In this article, we are going to take a look at where Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) stands against other best performing mid cap stocks to buy according to analysts. On February 7 ...

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42. ...

Revenue: US$336.9m (up 81% from FY 2023). Net loss: US$87.9m (loss narrowed by 46% from FY 2023). US$1.85 loss per share (improved from US$4.00 loss in FY 2023). Revenue was in line with analyst ...

Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million for the quarter, compared to the consensus estimate of ...

16:06 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $420M-$435M vs. $336.4M in FY24 See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...

See today's pick now. The U.S. Food and Drug Administration (FDA) approved Mirum Pharmaceuticals, Inc’s MIRM drug to treat CTX, a very rare lipid storage disease. CTX is a genetic metabolic ...

Luke Herrmann; Analyst; Robert W. Baird & Co., Inc. Hello, and welcome to Mirum Pharmaceuticals reports fourth quarter and year-end 2024 financial results and provides business update. My name is ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on MIRM: Mirum Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2024 financial results on Wednesday, February 26 ...

Hello, and welcome to Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update. My name is Elliot, and I'll be your coordinator today.